Immune Therapeutics to Present at the SeeThruEquity 1st Annual Microcap Healthcare Investor Conference

SAN FRANCISCO, CA / ACCESSWIRE / January 11, 2016 / Immune Therapeutics, Inc. (OTCQB: IMUN) a biotechnology company working to combat chronic, life-threatening diseases through the activation and modulation of the body’s immune system using its patented immunotherapy, will present at the SeeThruEquity First Annual Microcap Healthcare Investor Conference on Monday, January 11th, 2016 at The Fairmont in San Francisco, California.

Immune Therapeutics’ CEO, Noreen Griffin, will begin the presentation at 3:30 p.m. PST and will provide an overview of the major 2015 milestones and a 2016 outlook. In a 30-minute presentation, Immune Therapeutics will showcase the Company’s groundbreaking treatments for cancer, infections such as HIV/AIDS, chronic inflammatory diseases, and autoimmune diseases, and showcase the 2016 product roadmap and global distribution strategy. The Company will also be participating in 1-on-1 meetings throughout the day.

The SeeThruEquity Microcap Healthcare Investor Conference is the premier microcap conference focused on providing equity research to institutional and high net worth investors. Since its inception in 2011, the firm has grown to over 165 companies under coverage and has successfully hosted 17 investor conferences. This conference will bring together 25 presenting companies with more than 300 attendees. Attendees will enjoy detailed presentations, targeted one on one meetings, and numerous networking opportunities. For more information or to register, please visit the conference website at http://steconference.com.

About SeeThruEquity

SeeThruEquity is an equity research and corporate access firm focused on companies with less than $1 billion in market capitalization. Their research is not paid for and is unbiased. They do not conduct any investment banking or commission based business. They are approved to contribute their research to Thomson Reuters One (First Call), CapitalIQ, FactSet, and Zacks and distribute their research to their database of opt-in investors. They also contribute our estimates to Thomson Estimates, the leading estimates platform on Wall Street. For more information, visit www.seethruequity.com.

About Immune Therapeutics, Inc.

Immune Therapeutics products and immunotherapy technologies are designed to harness the power of the immune system to improve the treatment of cancer, infections such as HIV/AIDS, chronic inflammatory diseases, and autoimmune diseases. Its proprietary technology, therapies and patents include the treatment of a wide range of cancers. The Company’s most advanced clinical programs involve immunotherapy with metenkephalin (MENK) (sometimes referred to as opioid growth factor) and its Low Dose Naltrexone product (LDN) or Lodonal(TM), which have been shown to stimulate the immune system even in patients with advanced cancer. Immune considers conditions that result in altered‐immune response a target for investigation and, pending availability of funding and resources, will pursue additional investigations for MENK and LDN as valuable candidates in the treatment of autoimmune states such as: Rheumatoid arthritis and multiple sclerosis; adjunct therapy in cancer patients undergoing chemotherapy, radiation treatments or surgery; and as a compliment to antibiotics in the treatment of a variety of infectious diseases, including HIV/AIDS, possibly in combination with retroviral drug therapy.

Online: https://www.immunetherapeutics.com/
Social media: https://www.facebook.com/ImmuneTherapeutics

General information, licensing or investor relations email:

info@immunetherapeutics.com
(561) 408-1064

Disclaimer: IMUN does not warrant or represent that the unauthorized use of materials drawn from the content of this document will not infringe rights of third parties who are not owned or affiliated by IMUN. Further IMUN cannot be held responsible or liable for the unauthorized use of this document’s content by third parties unknown to the company.

Forward Looking Statements

This news release contains forward-looking statements. The terms and phrases “expects,” “would,” “will,” “believes,” and similar terms and phrases are intended to identify these forward-looking statements. Forward-looking statements are based on estimates and assumptions made by IMUN in light of its experience and its perception of current conditions and expected future developments, as well as other factors that IMUN believes are appropriate in the circumstances. Many factors could cause IMUN’s actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statements. Certain risk factors that may cause actual results to differ are set forth in IMUN’s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (which may be obtained at http://www.sec.gov). These factors should be considered carefully, and readers should not place undue reliance on IMUNs forward-looking statements. IMUN has no intention and undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

SOURCE: Immune Therapeutics, Inc.

ReleaseID: 435498